Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Shares Shorted: Short Interest Down 76.0% in September

Posted by Stanley Muller on Sep 26th, 2026

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Get Free Report) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 126,292 shares, a drop of 76.0% from the August 31st total of 526,654 shares. Based on an average trading volume of 152,599 shares, the days-to-cover ratio is currently 0.8 days. Currently, 7.1% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on QNRX shares. ThinkEquity started coverage on shares of Quoin Pharmaceuticals in a report on Monday, June 15th. They set a “buy” rating for the company. Lake Street Capital started coverage on Quoin Pharmaceuticals in a report on Wednesday. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.00.

Check Out Our Latest Report on QNRX

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock traded up $0.05 on Friday, hitting $6.43. 11,014 shares of the company’s stock traded hands, compared to its average volume of 1,670,566. The stock has a market capitalization of $12.92 million, a price-to-earnings ratio of -0.26 and a beta of 1.51. The company’s fifty day simple moving average is $5.67 and its 200 day simple moving average is $5.70. Quoin Pharmaceuticals has a one year low of $3.25 and a one year high of $41.80.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($1.61) by ($0.29). As a group, sell-side analysts anticipate that Quoin Pharmaceuticals will post -7.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Michael Myers acquired 20,490 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were bought at an average cost of $4.88 per share, for a total transaction of $99,991.20. Following the completion of the transaction, the chief executive officer owned 37,713 shares in the company, valued at approximately $184,039.44. This trade represents a 118.97% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Denise P. Carter bought 20,490 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was bought at an average cost of $4.88 per share, for a total transaction of $99,991.20. Following the completion of the purchase, the chief operating officer directly owned 37,709 shares of the company’s stock, valued at $184,019.92. This represents a 119.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 57,370 shares of company stock worth $279,966 over the last three months. Company insiders own 11.17% of the company’s stock.

Institutional Trading of Quoin Pharmaceuticals

An institutional investor recently raised its stake in Quoin Pharmaceuticals stock. SummitTX Capital L.P. increased its position in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX – Free Report) by 54.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,300 shares of the company’s stock after buying an additional 35,505 shares during the quarter. SummitTX Capital L.P. owned 5.56% of Quoin Pharmaceuticals worth $662,000 as of its most recent filing with the Securities & Exchange Commission. 8.63% of the stock is currently owned by institutional investors.

About Quoin Pharmaceuticals

(Get Free Report)

Quoin Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases, with an initial emphasis on serious dermatological conditions. The company is developing proprietary topical formulations intended to deliver therapies directly to affected skin while addressing unmet medical needs in patient populations with limited treatment options.

Quoin’s lead product candidate, QRX003, is a topical lotion formulation of sirolimus being developed for the treatment of Netherton syndrome, a rare genetic skin disorder.